1/15
11:52 am
crnx
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral [Yahoo! Finance]
Low
Report
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral [Yahoo! Finance]
1/12
04:05 pm
crnx
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/12
08:00 am
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $67.00 price target on the stock.
Low
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $67.00 price target on the stock.
1/10
12:21 pm
crnx
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data [Yahoo! Finance]
Medium
Report
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data [Yahoo! Finance]
1/8
08:02 am
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target lowered by analysts at Citizens Jmp from $108.00 to $105.00. They now have a "market outperform" rating on the stock.
Low
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target lowered by analysts at Citizens Jmp from $108.00 to $105.00. They now have a "market outperform" rating on the stock.
1/6
09:22 pm
crnx
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
High
Report
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
1/6
10:37 am
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Morgan Stanley from $77.00 to $80.00. They now have an "overweight" rating on the stock.
Low
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Morgan Stanley from $77.00 to $80.00. They now have an "overweight" rating on the stock.
1/5
04:02 pm
crnx
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Low
Report
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
1/5
09:38 am
crnx
Crinetics Pharmaceuticals Reports Palsonify Preliminary Revenue, Atumelnant Trial Progress [Yahoo! Finance]
Medium
Report
Crinetics Pharmaceuticals Reports Palsonify Preliminary Revenue, Atumelnant Trial Progress [Yahoo! Finance]
1/5
08:06 am
crnx
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia [Yahoo! Finance]
High
Report
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia [Yahoo! Finance]
1/5
08:00 am
crnx
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
Low
Report
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
1/4
04:00 pm
crnx
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
Medium
Report
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
1/3
01:06 am
crnx
Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by analysts at
Wall
Medium
Report
Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by analysts at
Wall
12/18
04:36 pm
crnx
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/18
04:05 pm
crnx
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
12/14
03:09 am
crnx
Does Crinetics Pharmaceuticals Still Offer Value After Its Recent Share Price Rebound? [Yahoo! Finance]
Low
Report
Does Crinetics Pharmaceuticals Still Offer Value After Its Recent Share Price Rebound? [Yahoo! Finance]
12/11
05:31 pm
crnx
Crinetics Pharmaceuticals Says First Patient Dosed in Phase 3 Trial of Atumelnant for Classic CAH [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Says First Patient Dosed in Phase 3 Trial of Atumelnant for Classic CAH [Yahoo! Finance]
12/11
04:47 pm
crnx
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) [Yahoo! Finance]
Low
Report
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) [Yahoo! Finance]
12/11
04:05 pm
crnx
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Low
Report
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
12/11
11:30 am
crnx
Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler [Yahoo! Finance]
12/10
05:10 pm
crnx
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/10
04:34 pm
crnx
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
08:00 am
crnx
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
High
Report
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
11/20
04:05 pm
crnx
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
Low
Report
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
11/10
04:28 pm
crnx
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)